Pharma Medicines

Product Details:

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. ... Dutasteride is not approved for prevention of prostate cancer.

Additional Information:

• Item Code: DUT123
• Production Capacity: N/A
• Delivery Time: 10 Days

Product Details:

Dutas 0.5mg Soft Gelatin Capsule is a 5-alpha reductase inhibitors. It blocks an enzyme which is necessary to change
to another hormone that causes the prostate to grow. As a result, it helps to shrink the prostate and relieve the symptoms like difficulty in passing urine.

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer),paypal wire transfer
• Port of Dispatch: mumbai
• Delivery Time: 5-7 days

Product Details:

Forteo 600mcg Injection is a synthetic form of a natural human hormone called parathyroid hormone (PTH). It works by activating cells that build up bone and increase bone strength, thereby minimizing the risk of fractures. used mainly for treating osteoporosis.

Product Details:

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
Safety controversyIn April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[3] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.
COVID-19In late July 2020 Merck, which had been partnering with Ridgeback Biotherapeutics on developing the drug, announced its intention to move molnupiravir to late stage trials beginning in September 2020. On October 19 2020, Merck began a one year Stage 2/3 trial focused on hospitalized patients.

Product Details: